BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Jon P. Stonehouse
CEOJon P. Stonehouse
Employees
580
Employees580
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
580
Employees580

BCRX Key Statistics

Market cap
1.61B
Market cap1.61B
Price-Earnings ratio
-162.79
Price-Earnings ratio-162.79
Dividend yield
Dividend yield
Average volume
3.79M
Average volume3.79M
High today
$7.69
High today$7.69
Low today
$7.53
Low today$7.53
Open price
$7.69
Open price$7.69
Volume
961.88K
Volume961.88K
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

With a market cap of 1.61B, BioCryst(BCRX) trades at $7.62. The stock has a price-to-earnings ratio of -162.79.

On 2025-12-26, BioCryst(BCRX) stock moved within a range of $7.53 to $7.69. With shares now at $7.62, the stock is trading +1.2% above its intraday low and -0.9% below the session's peak.

Trading volume for BioCryst(BCRX) stock has reached 961.88K, versus its average volume of 3.79M.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

Over the past 52 weeks, BioCryst(BCRX) stock has traded between a high of $11.31 and a low of $6.00.

BCRX News

Simply Wall St 2d
BioCryst Pharmaceuticals Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children

BioCryst Pharmaceuticals previously announced that the FDA approved its New Drug Application for an oral pellet formulation of once-daily ORLADEYO (berotralstat...

BioCryst Pharmaceuticals Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children
TipRanks 3d
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger

Claim 70% Off TipRanks This Holiday Season An announcement from Astria Therapeutics ( (ATXS) ) is now available. On October 14, 2025, Astria Therapeutics ente...

Analyst ratings

90%

of 10 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.